Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 9485 Neoplasms 6599 Prostatic Neoplasms 4404 Colorectal Neoplasms 3979 Lung Neoplasms 3647 Carcinoma, Non-Small-Cell Lung 3587 Pancreatic Neoplasms 2480 Carcinoma, Hepatocellular 2416 Leukemia, Myeloid, Acute 2266 Multiple Myeloma 2123 Stomach Neoplasms 2109 Neoplasm Metastasis 1913 Head and Neck Neoplasms 1873 Ovarian Neoplasms 1778 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1734 Lymphoma 1731 Brain Neoplasms 1706 Rectal Neoplasms 1676 Melanoma 1657 Colonic Neoplasms 1629 Uterine Cervical Neoplasms 1501 Leukemia 1500 Recurrence 1486 Esophageal Neoplasms 1312 Glioblastoma 1310 Lymphoma, Non-Hodgkin 1205 Leukemia, Lymphocytic, Chronic, B-Cell 1120 Squamous Cell Carcinoma of Head and Neck 1109 Urinary Bladder Neoplasms 1080 Lymphoma, Follicular 1069

Interventions

Cholecalciferol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Vitamin D3 × Clear all

NCT03389659 2018-01-03

XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC

Tianjin Medical University Cancer Institute and Hospital

Phase 3 Unknown

Vitamin D3

Data powered by HemOnc (CC BY 4.0) Colophon ⚡